Načítá se...

Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma.

BACKGROUND--A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. To investigate the mechanism of action of auranofin the bronchial responsiveness to inhaled methacholine has been studied in well controlle...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Honma, M., Tamura, G., Shirato, K., Takishima, T.
Médium: Artigo
Jazyk:Inglês
Vydáno: 1994
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC475050/
https://ncbi.nlm.nih.gov/pubmed/8066558
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!